Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity ; volume:8 ; number:1 ; day:16 ; month:8 ; year:2018 ; pages:1-10 ; date:12.2018
Scientific reports ; 8, Heft 1 (16.8.2018), 1-10, 12.2018
- Urheber
-
Lee, Jin Hee
- Beteiligte Personen und Organisationen
-
Jung, Kyung-Ho
Quach, Cung Hoa Thien
Park, Jin Won
Moon, Seung Hwan
Cho, Young Seok
Lee, Kyung-Han
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-29642-w
- URN
-
urn:nbn:de:101:1-2018101000191462079641
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Jin Hee
- Jung, Kyung-Ho
- Quach, Cung Hoa Thien
- Park, Jin Won
- Moon, Seung Hwan
- Cho, Young Seok
- Lee, Kyung-Han
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs
2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs
2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy
Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B
Bortezomib
Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs
2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy